{"success":true,"data":{"pressRelease":{"id":"18798","rtpr_id":"nBwB0HBa","ticker":"ARWR","exchange":"NASDAQ","all_tickers":["ARWR"],"title":"Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events","author":"Business Wire","published_at":"2026-05-04T11:30:00.095Z","article_body":"Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events\n\nArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is\nscheduled to participate in the following upcoming events:\n\nBofA Securities 2026 Healthcare Conference – May 12-14, 2026\n\nType: Investor Group Dinner\n\nDate/Time: May 12, 2026\n\nType: Fireside Chat Presentation\n\nDate/Time: May 13, 2026, 10:00 am PDT\n\nTIDES USA Oligonucleotide & Peptide Therapeutics – May 11-14 in Boston,\nMassachusetts\n\nTitle: Systemic RNAi Targeting MAPT: Advancing Tau Suppression Across the CNS\nwith TRiM™ SC\n\nDate/Time: May 13, 2026, 4:45 PM EDT\n\nPresenter: Kayal Madhivanan\n\n33rd European Congress on Obesity (ECO 2026) – May 12-15 in Istanbul,\nTürkiye\n\nTitle: Elevated Activin E levels correlate with insulin resistance and\nmetabolic dysfunction in non-human primates and adult patients with obesity\nand type 2 diabetes\n\nDate/Time: May 13-14; 1:00 PM – 3:00 PM\n\nPresenter: Jane Kerr, MBChB, MPH, DRCOG\n\n2026 RBC Capital Markets Global Healthcare Conference – May 19-20, 2026\n\nType: Fireside Chat Presentation\n\nDate/Time: May 20, 2026, 9:00 am EDT\n\nEuropean Atherosclerosis Society (EAS 2026) Congress – May 24-27 in Athens,\nGreece\n\n2 Oral Presentations:\n\nTitle: PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF PLOZASIRAN IN\nSUBJECTS WITH RENAL OR HEPATIC IMPAIRMENT\n\nSession: Late Breaker Clinical Abstracts\n\nDate/Time: May 26, 2026, 5:00 AM – 5:15 PM\n\nPresenter: Jennifer Hellawell, MD\n\nTitle: A CASE REPORT OF A PREGNANT WOMAN WITH FAMILIAL CHYLOMICRONEMIA\nSYNDROME TREATED WITH PLOZASIRAN, A SMALL INTERFERING RNA AGAINST APOC3\n\nSession: EAS stage: Outreach and case presentations\n\nDate/Time: May 26, 2026, 8:30 AM – 10:30 AM\n\nPresenter: Ann Mertens, MD\n\nEuropean Association for the Study of the Liver (EASL 2026) – May 27-30 in\nBarcelona, Spain\n\nTitle: ARO‑INHBE demonstrates clinically meaningful reductions in liver fat\nas monotherapy and in combination with low-dose tirzepatide in adults with\nobesity\n\nLate Breaker Poster Session\n\nPresenter: Rinki Murphy, MBChB, PhD\n\nPresentation materials and webcast links, if applicable, may be accessed on\nthe Events and Presentations\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fir.arrowheadpharma.com%2Fevents-and-presentations&esheet=54527368&newsitemid=20260504575415&lan=en-US&anchor=Events+and+Presentations&index=1&md5=db84a4f81fded627a52b408cdf0a844e)\npage under the Investors section of the Arrowhead website.\n\nAbout Arrowhead Pharmaceuticals\n\nArrowhead Pharmaceuticals (NASDAQ: ARWR) is a commercial-stage pharmaceutical\ncompany developing medicines that treat intractable diseases by silencing the\ngenes that cause them, harnessing the natural RNA interference (RNAi)\nmechanism. The company has built a broad portfolio of clinical and commercial\nRNAi therapeutics through its industry-leading targeted RNAi molecule\n(TRiM™) platform, which can precisely silence genes in a wide range of cell\ntypes, including liver, lung, muscle, adipose, and central nervous system\ntissue. At Arrowhead, we rapidly advance potential best- and first-in-class\nRNAi treatments for diseases with significant unmet medical need, because\nevery day matters to the patients we serve.\n\nFor more information, please visit arrowheadpharma.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Farrowheadpharma.com%2F&esheet=54527368&newsitemid=20260504575415&lan=en-US&anchor=arrowheadpharma.com&index=2&md5=51b89cc6048d9652a0bb46d9abb8cad7)\n, or follow us on X (formerly Twitter) at @ArrowheadPharma\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2Farrowheadpharma&esheet=54527368&newsitemid=20260504575415&lan=en-US&anchor=%40ArrowheadPharma&index=3&md5=71c8c303a3657387980c42137f23a0fa)\n, LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Farrowhead-pharmaceuticals%2F&esheet=54527368&newsitemid=20260504575415&lan=en-US&anchor=LinkedIn&index=4&md5=f1fc8474a9ea7359b5b83ed2276b59b3)\n, Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FArrowheadPharma%2F&esheet=54527368&newsitemid=20260504575415&lan=en-US&anchor=Facebook&index=5&md5=738a67075ffb71c58dc8d6a6399acfa0)\n, and Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Farrowheadpharma%2F&esheet=54527368&newsitemid=20260504575415&lan=en-US&anchor=Instagram&index=6&md5=f6ed3542b25245c1ef432f753cdff579)\n. To be added to the Company’s email list and receive news directly, please\nvisit ir.arrowheadpharma.com/email-alerts\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fir.arrowheadpharma.com%2Femail-alerts&esheet=54527368&newsitemid=20260504575415&lan=en-US&anchor=ir.arrowheadpharma.com%2Femail-alerts&index=7&md5=ec32e7ac22ee9d11fdda28db4f108b45)\n.\n\nSafe Harbor Statement under the Private Securities Litigation Reform Act:\n\nThis news release contains forward-looking statements within the meaning of\nthe \"safe harbor\" provisions of the Private Securities Litigation Reform Act\nof 1995. Any statements contained in this release except for historical\ninformation may be deemed to be forward-looking statements. Without limiting\nthe generality of the foregoing, words such as “may,” “will,”\n“expect,” “believe,” “anticipate,” “hope,” “intend,”\n“plan,” “project,” “could,” “estimate,” “continue,”\n“target,” “forecast” or “continue” or the negative of these words\nor other variations thereof or comparable terminology are intended to identify\nsuch forward-looking statements. In addition, any statements that refer to\nprojections of our future financial performance, trends in our business,\nexpectations for our product pipeline or product candidates, including\nanticipated regulatory submissions and clinical program results, prospects or\nbenefits of our collaborations with other companies, or other\ncharacterizations of future events or circumstances are forward-looking\nstatements. These forward-looking statements include, but are not limited to,\nstatements about the initiation, timing, progress and results of our\npreclinical studies and clinical trials, and our research and development\nprograms; our expectations regarding the potential benefits of the\npartnership, licensing and/or collaboration arrangements and other strategic\narrangements and transactions we have entered into or may enter into in the\nfuture; our beliefs and expectations regarding milestone, royalty or other\npayments that could be due to or from third parties under existing agreements;\nand our estimates regarding future revenues, research and development\nexpenses, capital requirements and payments to third parties. These statements\nare based upon our current expectations and speak only as of the date hereof.\nOur actual results may differ materially and adversely from those expressed in\nany forward-looking statements as a result of numerous factors and\nuncertainties, including the safety and efficacy of our product candidates,\ndecisions of regulatory authorities and the timing thereof, the duration and\nimpact of regulatory delays in our clinical programs, our ability to finance\nour operations, the likelihood and timing of the receipt of future milestone\nand licensing fees, the future success of our scientific studies, our ability\nto successfully develop and commercialize drug candidates, the timing for\nstarting and completing clinical trials, rapid technological change in our\nmarkets, the enforcement of our intellectual property rights, and the other\nrisks and uncertainties described in our most recent Annual Report on Form\n10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with\nthe Securities and Exchange Commission from time to time. We assume no\nobligation to update or revise forward-looking statements to reflect new\nevents or circumstances.\n\nSource: Arrowhead Pharmaceuticals, Inc.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260504575415/en/\n(https://www.businesswire.com/news/home/20260504575415/en/)\n\nArrowhead Pharmaceuticals, Inc.\n\nVince Anzalone, CFA\n\n626-304-3400\n\nir@arrowheadpharma.com (mailto:ir@arrowheadpharma.com)\n\nInvestors: \n\nLifeSci Advisors, LLC\n\nBrian Ritchie\n\n212-915-2578\n\nbritchie@lifesciadvisors.com (mailto:britchie@lifesciadvisors.com)\n\nMedia: \n\nLifeSci Communications, LLC\n\nKendy Guarinoni, Ph.D.\n\n724-910-9389\n\nkguarinoni@lifescicomms.com (mailto:kguarinoni@lifescicomms.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBwB0HBa","title":"Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events","author":"Business Wire","ticker":"ARWR","created":"2026-05-04T11:30:00.095Z","tickers":["ARWR"],"exchange":"NASDAQ","article_body":"Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events\n\nArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is\nscheduled to participate in the following upcoming events:\n\nBofA Securities 2026 Healthcare Conference – May 12-14, 2026\n\nType: Investor Group Dinner\n\nDate/Time: May 12, 2026\n\nType: Fireside Chat Presentation\n\nDate/Time: May 13, 2026, 10:00 am PDT\n\nTIDES USA Oligonucleotide & Peptide Therapeutics – May 11-14 in Boston,\nMassachusetts\n\nTitle: Systemic RNAi Targeting MAPT: Advancing Tau Suppression Across the CNS\nwith TRiM™ SC\n\nDate/Time: May 13, 2026, 4:45 PM EDT\n\nPresenter: Kayal Madhivanan\n\n33rd European Congress on Obesity (ECO 2026) – May 12-15 in Istanbul,\nTürkiye\n\nTitle: Elevated Activin E levels correlate with insulin resistance and\nmetabolic dysfunction in non-human primates and adult patients with obesity\nand type 2 diabetes\n\nDate/Time: May 13-14; 1:00 PM – 3:00 PM\n\nPresenter: Jane Kerr, MBChB, MPH, DRCOG\n\n2026 RBC Capital Markets Global Healthcare Conference – May 19-20, 2026\n\nType: Fireside Chat Presentation\n\nDate/Time: May 20, 2026, 9:00 am EDT\n\nEuropean Atherosclerosis Society (EAS 2026) Congress – May 24-27 in Athens,\nGreece\n\n2 Oral Presentations:\n\nTitle: PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF PLOZASIRAN IN\nSUBJECTS WITH RENAL OR HEPATIC IMPAIRMENT\n\nSession: Late Breaker Clinical Abstracts\n\nDate/Time: May 26, 2026, 5:00 AM – 5:15 PM\n\nPresenter: Jennifer Hellawell, MD\n\nTitle: A CASE REPORT OF A PREGNANT WOMAN WITH FAMILIAL CHYLOMICRONEMIA\nSYNDROME TREATED WITH PLOZASIRAN, A SMALL INTERFERING RNA AGAINST APOC3\n\nSession: EAS stage: Outreach and case presentations\n\nDate/Time: May 26, 2026, 8:30 AM – 10:30 AM\n\nPresenter: Ann Mertens, MD\n\nEuropean Association for the Study of the Liver (EASL 2026) – May 27-30 in\nBarcelona, Spain\n\nTitle: ARO‑INHBE demonstrates clinically meaningful reductions in liver fat\nas monotherapy and in combination with low-dose tirzepatide in adults with\nobesity\n\nLate Breaker Poster Session\n\nPresenter: Rinki Murphy, MBChB, PhD\n\nPresentation materials and webcast links, if applicable, may be accessed on\nthe Events and Presentations\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fir.arrowheadpharma.com%2Fevents-and-presentations&esheet=54527368&newsitemid=20260504575415&lan=en-US&anchor=Events+and+Presentations&index=1&md5=db84a4f81fded627a52b408cdf0a844e)\npage under the Investors section of the Arrowhead website.\n\nAbout Arrowhead Pharmaceuticals\n\nArrowhead Pharmaceuticals (NASDAQ: ARWR) is a commercial-stage pharmaceutical\ncompany developing medicines that treat intractable diseases by silencing the\ngenes that cause them, harnessing the natural RNA interference (RNAi)\nmechanism. The company has built a broad portfolio of clinical and commercial\nRNAi therapeutics through its industry-leading targeted RNAi molecule\n(TRiM™) platform, which can precisely silence genes in a wide range of cell\ntypes, including liver, lung, muscle, adipose, and central nervous system\ntissue. At Arrowhead, we rapidly advance potential best- and first-in-class\nRNAi treatments for diseases with significant unmet medical need, because\nevery day matters to the patients we serve.\n\nFor more information, please visit arrowheadpharma.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Farrowheadpharma.com%2F&esheet=54527368&newsitemid=20260504575415&lan=en-US&anchor=arrowheadpharma.com&index=2&md5=51b89cc6048d9652a0bb46d9abb8cad7)\n, or follow us on X (formerly Twitter) at @ArrowheadPharma\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2Farrowheadpharma&esheet=54527368&newsitemid=20260504575415&lan=en-US&anchor=%40ArrowheadPharma&index=3&md5=71c8c303a3657387980c42137f23a0fa)\n, LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Farrowhead-pharmaceuticals%2F&esheet=54527368&newsitemid=20260504575415&lan=en-US&anchor=LinkedIn&index=4&md5=f1fc8474a9ea7359b5b83ed2276b59b3)\n, Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FArrowheadPharma%2F&esheet=54527368&newsitemid=20260504575415&lan=en-US&anchor=Facebook&index=5&md5=738a67075ffb71c58dc8d6a6399acfa0)\n, and Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Farrowheadpharma%2F&esheet=54527368&newsitemid=20260504575415&lan=en-US&anchor=Instagram&index=6&md5=f6ed3542b25245c1ef432f753cdff579)\n. To be added to the Company’s email list and receive news directly, please\nvisit ir.arrowheadpharma.com/email-alerts\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fir.arrowheadpharma.com%2Femail-alerts&esheet=54527368&newsitemid=20260504575415&lan=en-US&anchor=ir.arrowheadpharma.com%2Femail-alerts&index=7&md5=ec32e7ac22ee9d11fdda28db4f108b45)\n.\n\nSafe Harbor Statement under the Private Securities Litigation Reform Act:\n\nThis news release contains forward-looking statements within the meaning of\nthe \"safe harbor\" provisions of the Private Securities Litigation Reform Act\nof 1995. Any statements contained in this release except for historical\ninformation may be deemed to be forward-looking statements. Without limiting\nthe generality of the foregoing, words such as “may,” “will,”\n“expect,” “believe,” “anticipate,” “hope,” “intend,”\n“plan,” “project,” “could,” “estimate,” “continue,”\n“target,” “forecast” or “continue” or the negative of these words\nor other variations thereof or comparable terminology are intended to identify\nsuch forward-looking statements. In addition, any statements that refer to\nprojections of our future financial performance, trends in our business,\nexpectations for our product pipeline or product candidates, including\nanticipated regulatory submissions and clinical program results, prospects or\nbenefits of our collaborations with other companies, or other\ncharacterizations of future events or circumstances are forward-looking\nstatements. These forward-looking statements include, but are not limited to,\nstatements about the initiation, timing, progress and results of our\npreclinical studies and clinical trials, and our research and development\nprograms; our expectations regarding the potential benefits of the\npartnership, licensing and/or collaboration arrangements and other strategic\narrangements and transactions we have entered into or may enter into in the\nfuture; our beliefs and expectations regarding milestone, royalty or other\npayments that could be due to or from third parties under existing agreements;\nand our estimates regarding future revenues, research and development\nexpenses, capital requirements and payments to third parties. These statements\nare based upon our current expectations and speak only as of the date hereof.\nOur actual results may differ materially and adversely from those expressed in\nany forward-looking statements as a result of numerous factors and\nuncertainties, including the safety and efficacy of our product candidates,\ndecisions of regulatory authorities and the timing thereof, the duration and\nimpact of regulatory delays in our clinical programs, our ability to finance\nour operations, the likelihood and timing of the receipt of future milestone\nand licensing fees, the future success of our scientific studies, our ability\nto successfully develop and commercialize drug candidates, the timing for\nstarting and completing clinical trials, rapid technological change in our\nmarkets, the enforcement of our intellectual property rights, and the other\nrisks and uncertainties described in our most recent Annual Report on Form\n10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with\nthe Securities and Exchange Commission from time to time. We assume no\nobligation to update or revise forward-looking statements to reflect new\nevents or circumstances.\n\nSource: Arrowhead Pharmaceuticals, Inc.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260504575415/en/\n(https://www.businesswire.com/news/home/20260504575415/en/)\n\nArrowhead Pharmaceuticals, Inc.\n\nVince Anzalone, CFA\n\n626-304-3400\n\nir@arrowheadpharma.com (mailto:ir@arrowheadpharma.com)\n\nInvestors: \n\nLifeSci Advisors, LLC\n\nBrian Ritchie\n\n212-915-2578\n\nbritchie@lifesciadvisors.com (mailto:britchie@lifesciadvisors.com)\n\nMedia: \n\nLifeSci Communications, LLC\n\nKendy Guarinoni, Ph.D.\n\n724-910-9389\n\nkguarinoni@lifescicomms.com (mailto:kguarinoni@lifescicomms.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-05-04T11:30:00.146108732Z","server_sent_at_ms":1777894200146},"received_at":"2026-05-04T11:30:00.200Z","source_url":"https://www.businesswire.com/news/home/20260504575415/en/"},"analysis":{"id":"13610","press_release_id":"18798","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Arrowhead Pharmaceuticals announced its participation in several upcoming May 2026 conferences, including the BofA Securities Healthcare Conference and RBC Capital Markets Global Healthcare Conference.\n\nThe company will present data on several assets, including late-breaker abstracts for PLOZASIRAN at EAS 2026 and new data for ARO-INHBE at EASL 2026.\n\nPresentation materials will be available on the company's investor relations website.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference participation update."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Kayal Madhivanan","role":"Presenter"},{"name":"Jane Kerr","role":"Presenter"},{"name":"Jennifer Hellawell","role":"Presenter"},{"name":"Ann Mertens","role":"Presenter"},{"name":"Rinki Murphy","role":"Presenter"},{"name":"Vince Anzalone","role":"Contact"}],"products":["PLOZASIRAN","ARO-INHBE","TRiM™ SC","tirzepatide"],"companies":[{"name":"Arrowhead Pharmaceuticals, Inc.","ticker":"ARWR"},{"name":"BofA Securities","relationship":"conference organizer"},{"name":"RBC Capital Markets","relationship":"conference organizer"},{"name":"LifeSci Advisors, LLC","relationship":"investor relations"},{"name":"LifeSci Communications, LLC","relationship":"media relations"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Standard corporate calendar update announcing upcoming conference participation and presentation titles. Routine disclosure with no clinical, regulatory, or financial data released."},"tickerRelevance":{"others":[],"primary":"ARWR"},"globalImportance":10,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","dataRelease":false,"eventGravity":"conference-calendar"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Arrowhead Pharmaceuticals announced its participation in several upcoming May 2026 conferences, including the BofA Securities Healthcare Conference and RBC Capital Markets Global Healthcare Conference.\n\nThe company will present data on several assets, including late-breaker abstracts for PLOZASIRAN at EAS 2026 and new data for ARO-INHBE at EASL 2026.\n\nPresentation materials will be available on the company's investor relations website.","key_figures":{},"named_entities":{"people":[{"name":"Kayal Madhivanan","role":"Presenter"},{"name":"Jane Kerr","role":"Presenter"},{"name":"Jennifer Hellawell","role":"Presenter"},{"name":"Ann Mertens","role":"Presenter"},{"name":"Rinki Murphy","role":"Presenter"},{"name":"Vince Anzalone","role":"Contact"}],"products":["PLOZASIRAN","ARO-INHBE","TRiM™ SC","tirzepatide"],"companies":[{"name":"Arrowhead Pharmaceuticals, Inc.","ticker":"ARWR"},{"name":"BofA Securities","relationship":"conference organizer"},{"name":"RBC Capital Markets","relationship":"conference organizer"},{"name":"LifeSci Advisors, LLC","relationship":"investor relations"},{"name":"LifeSci Communications, LLC","relationship":"media relations"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-04T13:07:08.836Z","global_importance":10,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap","dataRelease":false,"eventGravity":"conference-calendar"}},"durationMs":31864,"modelName":"glm-4.7"}}